|
| 37881148 | Rebuttal to comment on "Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer". | Head Neck | 2024 |
| 36305841 | Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer. | CA Cancer J Clin | 2023 |
| 37627175 | <i>RET</i>-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity. | Cancers (Basel) | 2023 |
| 37620627 | Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial. | Nat Med | 2023 |
| 35801573 | Outcomes for Organ Preservation with Chemoradiation Therapy for T4 Larynx and Hypopharynx Cancer. | Laryngoscope | 2023 |
| 37439286 | Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer. | Head Neck | 2023 |
| 37435097 | Stem cell-like T cell depletion in the recurrent head and neck cancer immune microenvironment. | Oncoimmunology | 2023 |
| 37099979 | Post-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity. | Oral Oncol | 2023 |
| 36549347 | Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer. | Int J Radiat Oncol Biol Phys | 2023 |
| 36689229 | Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma. | JAMA Netw Open | 2023 |
| 36681089 | Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial. | Lancet Oncol | 2023 |
| 34449926 | Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases. | Histopathology | 2022 |
| 35383193 | Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. | Nat Commun | 2022 |
| 35679031 | Association of Low and Intermediate Combined Positive Scores With Outcomes of Treatment With Pembrolizumab in Patients With Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: Secondary Analysis of Keynote 048. | JAMA Oncol | 2022 |
| 35704797 | Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. | JCO Precis Oncol | 2022 |
| 35521657 | A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. | Thyroid | 2022 |
| 35969032 | LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve <i>RET</i>-mutant medullary thyroid cancer. | Future Oncol | 2022 |
| 35867947 | Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404). | J Clin Oncol | 2022 |
| 36367724 | Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy. | JAMA Netw Open | 2022 |
| 36060412 | Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy. | Int J Part Ther | 2022 |
| 36264562 | Methodologic Concerns in Secondary Analysis of KEYNOTE-048-Reply. | JAMA Oncol | 2022 |
| 35045748 | Enhancing Radioiodine Incorporation in <i>BRAF</i>-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. | Thyroid | 2022 |
| 35274388 | American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. | Head Neck | 2022 |
| 35304457 | The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. | Nat Commun | 2022 |
| 35050342 | Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus-Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy. | JAMA Oncol | 2022 |
| 35333737 | Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. | Eur J Endocrinol | 2022 |
| 34789562 | Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity. | Mol Cancer Ther | 2022 |
| 34635506 | Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy. | Mol Cancer Res | 2022 |
| 34716196 | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT. | Clin Cancer Res | 2022 |
| 32822275 | Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. | J Clin Oncol | 2021 |
| 33586179 | Any day, split halfway: Flexibility in scheduling high-dose cisplatin-A large retrospective review from a high-volume cancer center. | Int J Cancer | 2021 |
| 33890869 | Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers. | Endocr Relat Cancer | 2021 |
| 33606323 | Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy. | Head Neck | 2021 |
| 34381934 | <i>TERT</i> Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. | JCO Precis Oncol | 2021 |
| 34585792 | The effect of short radiation treatment breaks on chemo-radiotherapy for oropharyngeal cancers. | Head Neck | 2021 |
| 33961488 | Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. | J Clin Oncol | 2021 |
| 34293201 | Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. | Cancer | 2021 |
| 34143193 | Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy. | JAMA Netw Open | 2021 |
| 33429428 | Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. | J Natl Cancer Inst | 2021 |
| 31593317 | Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. | Cancer | 2020 |
| 31733124 | Outcomes of surgery and postoperative radiation therapy in managing medullary thyroid carcinoma. | J Surg Oncol | 2020 |
| 32029534 | Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> <sup>V600</sup>-Mutant Non-Melanoma Cancers. | Cancer Discov | 2020 |
| 32097507 | Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies. | Cancer | 2020 |
| 31678634 | A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma. | Int J Radiat Oncol Biol Phys | 2020 |
| 32650256 | Past, present and future of proton therapy for head and neck cancer. | Oral Oncol | 2020 |
| 32846061 | Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid Cancers. | N Engl J Med | 2020 |
| 32701124 | The Importance of Locoregional Therapy in Metastatic Nasopharyngeal Cancer. | JAMA Oncol | 2020 |
| 32639615 | The 3 Bs of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind"-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer. | Cancer | 2020 |
| 32582816 | Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base. | Int J Part Ther | 2020 |
| 32313184 | Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. | Mod Pathol | 2020 |